as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. *Hum Mol Genet* 20: 1034–1041.

Robinson, J., Mistry, K., McWilliam, H., Lopez, R., Parham, P. and Marsh, S. (2011) The IMGT/HLA database. *Nucleic Acids Res* 39(Suppl. 1): D1171–F1176.

Tassaneeyakul, W., Tiamkao, S., Jantararoungtong, T., Chen, P., Lin, S., Chen, W. *et al.* (2010) Association between *HLA-B*1502* and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. *Epilepsia* 51: 926–930.

Uchiyama, K., Kubota, F., Ariyoshi, N., Matsumoto, J., Ishii, I. and Kitada, M. (2013) Development of a simple method for detection of *HLA-A*31:01* allele. *Drug Metab Pharmacokinet* 12 February (Epub ahead of print).

Wang, Q., Zhou, J., Zhou, L., Chen, Z., Fang, Z., Chen, S. *et al.* (2011) Association between *HLA-B*1502* allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. *Seizure* 20: 446–448.

Wei, C., Chung, W., Huang, H., Chen, Y. and Hung, S. (2012) Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens–Johnson syndrome. *J Allergy Clin Immunol* 129: 1562–1569.

Yip, V., Marson, A., Jorgensen, A., Pirmohamed, M. and Alfirevic, A. (2012) HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. *Clin Pharmacol Ther* 92: 757–765.

Zhang, Y., Wang, J., Zhao, L., Peng, W., Shen, G., Xue, L. *et al.* (2011) Strong association between *HLA-B*1502* and carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. *Eur J Clin Pharmacol* 67: 885–887.